Picard Medical, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 24, 2025, reports a material definitive agreement entered into by Picard Medical, Inc. (PMI), a Delaware corporation and emerging growth company. The filing details a private placement transaction with a single institutional investor to secure funding for working capital and general corporate purposes.
Key Financial Metrics and Transaction Details
- Debt Issuance: Initial principal amount of $15,000,000 in senior secured notes due December 26, 2028.
- Interest Rate: 0.00% annual interest rate.
- Repayment Terms: Scheduled monthly amortization payments payable in cash or, at the Company's election, in kind via shares of Common Stock.
- Equity Component: Warrants issued to purchase 7,009,346 shares of Common Stock with an initial exercise price of $2.675.
- Additional Capacity: Option to issue up to an additional $35,000,000 in notes prior to December 15, 2028, subject to buyer consent.
- Liquidity Covenant: The Company must maintain a minimum of $4,000,000 in cash while the Notes remain outstanding.
- Transaction Costs: A cash fee of 7.5% of gross proceeds was paid to the placement agent, WestPark Capital, Inc., plus warrants for 5% of the aggregate shares issued.
Material Changes and Covenants
The transaction introduces significant new debt obligations and equity-linked securities. Key covenants and changes include:
- Security Interest: The Company granted a first-priority security interest in substantially all tangible and intangible assets, and its subsidiary SynCardia Systems, LLC granted a security interest in certain intellectual property.
- Issuance Restrictions: The Company is restricted from registering, offering, or issuing equity or equity-linked securities for 30 calendar days following the initial closing.
- Stockholder Approval: The Company must seek stockholder approval for the issuance of shares underlying the securities and an increase in authorized shares to at least 300 million at its next annual meeting.
- Registration Rights: A resale registration statement must be filed within 15 days of closing and become effective within 30 days (or 60 days if reviewed by the SEC).
- Participation Rights: The Buyer has a right to participate in up to 25% of future financings for 18 months or until the Notes are paid in full.
Outlook, Risks, and Unusual Items
The Company intends to use net proceeds for working capital and general corporate purposes. The filing notes that the Notes are senior secured obligations with customary events of default and acceleration remedies. The Warrants include a "cashless" exercise provision if the stock price exceeds 200% of the exercise price for 20 consecutive trading days. The filing does not provide specific revenue, profit, or cash flow figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Investor Verification Checklist
- Verify the Company's current cash balance to ensure compliance with the $4,000,000 minimum liquidity covenant.
- Review the full text of the Security Agreement and Intellectual Property Security Agreement to understand the scope of assets pledged as collateral.
- Confirm the timeline for the upcoming stockholder meeting required to approve the share issuance and authorized share increase.
- Assess the potential dilution impact of the 7,009,346 warrant shares and the potential issuance of up to 35 million in additional notes.
- Monitor the status of the resale registration statement filing and its effectiveness date.